GIPC2 and posterior cortical atrophy: Our findings are promising for a subset of patients with aggressive PCa in clinical trials evaluating WNT inhibitors, particularly for agents targeting WNT secretion and/or WNT receptor binding, and those preventing Fzd-family interaction with key factors, such as GIPC2 (Fig. 8j).